Deciphera Pharmaceuticals Inc

NASDAQ:DCPH   10:41:20 AM EDT
32.55
-0.73 (-2.19%)
Products, Regulatory

Deciphera Announces First Patient Treated In Phase 1 Study Of DCC-3116 In Patients With Advanced Or Metastatic Tumors

Published: 06/30/2021 20:13 GMT
Deciphera Pharmaceuticals Inc (DCPH) - Deciphera Announces First Patient Treated in Phase 1 Study of Dcc-3116 in Patients With Advanced Or Metastatic Tumors With a Mutant Ras Or Raf Gene.
Deciphera - Phase 1 Study Will Assess First-in-class Switch-control Ulk Kinase Inhibitor Designed to Inhibit Autophagy As a Single Agent.
Deciphera - Phase 1 Study Will Assess First-in-class Switch-control Ulk Kinase Inhibitor in Combination With Mek Inhibitor.